Carole Johnson Appears to be Leading Candidate to Run HRSA

A screen capture of a video of White House COVID-19 Testing Coordinator Carole Johnson during a briefing on the pandemic. Johnson reportedly will be named the next HRSA administrator.

After a 10-month delay, it looks like we may be getting close to the appointment of a permanent leader of the U.S. Health Resources and Services Administration (HRSA), the federal agency that runs the 340B drug pricing program.

News organization

Read More »

News Alert: HRSA Sets Wheels in Motion for a New 340B Administrative Dispute Resolution Proposed Rule

HRSA has asked the White House to review and approve a 340B administrative dispute resolution (ADR) proposed regulation.

The U.S. Health Resources and Services Administration (HRSA) yesterday asked the White House to review and approve a 340B administrative dispute resolution (ADR) proposed regulation for publication in the Federal Register.

The proposed rule’s purpose is unknown. HRSA published a

Read More »

For the First Time Since Pandemic, Some 340B Providers Are Being Audited in Person

HRSA has reconfirmed that it is auditing 340B covered entities for program compliance both remotely and in-person this fiscal year.

The U.S. Health Resources and Services Administration (HRSA) has reconfirmed that it is auditing 340B covered entities for program compliance both remotely and in-person this fiscal year.

HRSA told 340B Report in mid-September that in October it would resume

Read More »

CMS Delays Implementing Rule Allowing Multiple Best Prices for Drugs Until Next July

CMS announced late today that they are reversing significant Medicare cuts to 340B hospitals.

The Biden administration said yesterday it is delaying by six months the effective date of a Trump administration final rule to let drug manufacturers report multiple best prices on their products if states opt to participate in value-based purchasing (VBP)

Read More »

As Contract Pharmacy Losses Climb into the Billions, Fine for Overcharging 340B Providers Gets Closer to $6,000 Per Instance Mark

HHS OIG has raised the civil monetary penalty for overcharging a 340B covered entity to adjust for inflation.

The federal fine for overcharging a 340B covered entity just went up from $5,883.00 to $5,953.00 per each instance of overcharging.

The U.S. Health and Human Services Department (HHS) Office of Inspector General (OIG) posted its annual inflation adjustments to

Read More »

In Pursuit of New 340B Leader, HRSA Expands Its Search Beyond Pharmacists

In a major shift, HRSA has dropped its requirement that the Director of the Office of Pharmacy Affairs (OPA) must have a pharmacy degree and be a licensed pharmacist.

In a major organizational change, the U.S. Health Resources and Services Administration (HRSA) has redefined the job of Director of the Office of Pharmacy Affairs (OPA), the HRSA unit that runs the 340B program.

For the first time in 340B

Read More »

News Alert: CMS Will Continue Deep Cut in 340B Hospitals’ Medicare Part B Drug Reimbursement

CMS in 2022 will continue a nearly 30% reduction in place since 2018 in Medicare Part B reimbursement for many hospitals’ 340B-purchased drugs and biologicals.

In a big disappointment for 340B hospital organizations, the U.S. Centers for Medicare & Medicaid Services (CMS) announced late this afternoon that it will continue a nearly 30% reduction in place since 2018 in Medicare Part B reimbursement for hospitals’

Read More »

CMS Decision on Whether to Keep Part B Drug Payment Cuts for 340B Hospitals Could Come as Soon as Today

CMS could disclose as soon as today whether it will continue, end, or modify its nearly 30% cut in certain hospitals’ Medicare Part B reimbursement for 340B-purchased drugs.

The U.S. Centers for Medicare & Medicaid Services (CMS) could disclose as soon as today whether it will continue, end, or modify the nearly 30% cut in certain hospitals’ Medicare Part B reimbursement for 340B-purchased drugs.

The White House Office

Read More »

Biden Administration Wants to Scuttle Azar’s Rule to Automatically Snuff Out HHS Regulations

The Biden administration says it wants to withdraw or repeal ex-HHS Secretary Alex Azar’s final rule that will automatically extinguish all HHS regulations if HHS does not renew each regulation within a certain timeframe. | C-SPAN

The Biden administration last Friday, as widely expected, proposed withdrawing or repealing a Trump administration final rule that will automatically extinguish all U.S. Health and Human Services (HHS) regulations if HHS does not renew each regulation within a certain timeframe.

Read More »

340B Lobbying Intensifies on Capitol Hill and in Federal Agencies

2021 could be the runner up to 2018 in terms of 340B lobbying intensity, as measured by citations on lobbying disclosure forms.

2021 is on track to rival peak year 2018 in lobbying intensity on the 340B drug pricing program.

Attention on health care lobbying in Washington today focuses on the huge sums the drug industry is spending fighting Democratic drug price

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report